On Thursday, Celgene (NASDAQ:CELG) hosted its Q1 2014 call (transcript). During the question and answer portion of the call, a couple analysts asked questions regarding patent issues relating to Revlimid, Celgene's top selling drug.
Specifically, Matt Roden of UBS asked:
I realize you may be a little bit constrained in what you can talk about with the NATCO situation, but I was just wondering if you can talk about how a Markman outcome would actually impact the way you're dealing with the challenger? And is there any outcome in your opinion from the Markman that could swing a resolution one way or another?
Then, later, Yaron Werber of Citi asked:
I don't know if you can answer it with, when you look at what NATCO, their own IP that they filed relating to their essentially anhydrous Lenalidomide, one without water, it actually peaks to form A, which is your one of your polymers. And so, it's specifically the anhydrous polymer.
You guys are also alleging or you're using the form B, which is the hemihydrate. So what's going on, I mean, they're saying that they don't have water in their polymers that you guys are asserting your polymer that does have water. So give us a little bit of sense kind of where you're going with this, if you can. Thank you.
The company representatives on the call, including CEO Bob Hugin, responded to the questions as much as they could, but were limited in what they could say given the pending litigation between Celgene and Natco regarding the Revlimid patents.
To help shed some light on these issues, I recorded a quick video expanding upon the answers that were given by the company. The video is available from YouTube here.
A few of the key items I discuss in the video include the Natco situation, what Markman is and how it impacts the interpretation of Celgene's Revlimid patents, and the fact that Natco has its own patent application for a particular form of Revlimid. I hope the video is helpful in addressing questions the analysts, and others, have regarding patent issues relating to Celgene and its Revelimid product.
Disclosure: I am long CELG. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.